Whipplewood Advisors LLC Purchases New Holdings in Sanofi (NASDAQ:SNY)

Whipplewood Advisors LLC purchased a new stake in Sanofi (NASDAQ:SNY) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,579 shares of the company’s stock, valued at approximately $76,000.

Several other institutional investors have also recently added to or reduced their stakes in SNY. International Assets Investment Management LLC purchased a new stake in Sanofi in the 3rd quarter valued at approximately $7,038,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sanofi by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,721 shares of the company’s stock valued at $676,000 after purchasing an additional 2,100 shares in the last quarter. Arkadios Wealth Advisors purchased a new stake in Sanofi in the 3rd quarter valued at approximately $228,000. First Trust Direct Indexing L.P. boosted its holdings in Sanofi by 3.1% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 26,359 shares of the company’s stock valued at $1,519,000 after purchasing an additional 791 shares in the last quarter. Finally, Pinnacle Associates Ltd. boosted its holdings in Sanofi by 7.1% in the 3rd quarter. Pinnacle Associates Ltd. now owns 12,077 shares of the company’s stock valued at $696,000 after purchasing an additional 798 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $54.47 on Friday. The business’s 50 day simple moving average is $51.65 and its 200-day simple moving average is $52.61. The firm has a market capitalization of $138.24 billion, a price-to-earnings ratio of 21.88, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SNY has been the topic of a number of analyst reports. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.